Relationship between serum RANKL and RANKL in bone

被引：61

作者：

Findlay, D. M. ^{[1
,2
]}

Atkins, G. J. ^{[1
,2
]}

机构：

[1] Univ Adelaide, Discipline Orthopaed & Trauma, Royal Adelaide Hosp, Adelaide, SA 5000, Australia

[2] Hanson Inst, Adelaide, SA, Australia

来源：

OSTEOPOROSIS INTERNATIONAL | 2011年 / 22卷 / 10期

关键词：

Bone; mRNA; RANK ligand; Serum; KAPPA-B-LIGAND; SOLUBLE RECEPTOR-ACTIVATOR; OSTEOCLASTOGENESIS-INHIBITORY FACTOR; JUVENILE IDIOPATHIC ARTHRITIS; MESSENGER-RNA LEVELS; FORMATION IN-VITRO; CIRCULATING OSTEOPROTEGERIN; POSTMENOPAUSAL WOMEN; CLINICAL-IMPLICATIONS; RHEUMATOID-ARTHRITIS;

D O I：

10.1007/s00198-011-1740-9

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

It is now well accepted that the molecule receptor activator of NF kappa B ligand (RANKL) and osteoprotegerin play key roles in regulating physiological and pathological bone turnover. There are a large number of published reports of circulating RANKL levels in both health and pathology. However, interpretation of these data has been elusive, and the relationship between circulating RANKL and RANKL levels in bone is still not clear. This review explores this subject, documenting the possible origins of circulating RANKL and suggesting additional information that is required before serum RANKL levels can provide useful diagnostic or research information.

引用

页码：2597 / 2602

页数：6

共 59 条

[1]

Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins [J].

Abrahamsen, B ;

Hjelmborg, JV ;

Kostenuik, P ;

Stilgren, LS ;

Kyvik, K ;

Adamu, S ;

Brixen, K ;

Langdahl, BL .

BONE, 2005, 36 (04) :727-735

[2]

Serum osteoprotegerin and its ligand in Paget's disease of bone -: Relationship to disease activity and effect of treatment with bisphosphonates [J].

Alvarez, L ;

Peris, P ;

Guañabens, N ;

Vidal, S ;

Ros, I ;

Pons, F ;

Filella, X ;

Monegal, A ;

Muñoz-Gomez, J ;

Ballesta, AM .

ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :824-828

[3]

Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-κB ligand levels in women with established osteoporosis treated with teriparatide [J].

Anastasilakis, Athanasios D. ;

Goulis, Dimirtios G. ;

Polyzos, Stergios A. ;

Gerou, Spiridon ;

Pavlidou, Vasiliki ;

Koukoulis, George ;

Avramidis, Avraam .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (03) :411-415

[4]

Vitamin D Depletion Induces RANKL-Mediated Osteoclastogenesis and Bone Loss in a Rodent Model [J].

Anderson, Paul H. ;

Sawyer, Rebecca K. ;

Moore, Alison J. ;

May, Brian K. ;

O'Loughlin, Peter D. ;

Morris, Howard A. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 (11) :1789-1797

[5]

The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles [J].

Atkins, Gerald J. ;

Welldon, Katie J. ;

Holding, Christopher A. ;

Haynes, David R. ;

Howie, Donald W. ;

Findlay, David M. .

BIOMATERIALS, 2009, 30 (22) :3672-3681

[6]

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women [J].

Bone, Henry G. ;

Bolognese, Michael A. ;

Yuen, Chui Kin ;

Kendler, David L. ;

Wang, Huei ;

Liu, Yu ;

Martin, Javier San .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (06) :2149-2157

[7]

Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: Bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor κB ligand [J].

Bowsher, Ronald R. ;

Sailstad, Jeffrey M. .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 48 (05) :1282-1289

[8]

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].

Bucay, N ;

Sarosi, I ;

Dunstan, CR ;

Morony, S ;

Tarpley, J ;

Capparelli, C ;

Scully, S ;

Tan, HL ;

Xu, WL ;

Lacey, DL ;

Boyle, WJ ;

Simonet, WS .

GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268

[9]

Soluble receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation [J].

Chen, Chun-Hsiung ;

Chen, Hung-An ;

Liao, Hsien-Tzung ;

Liu, Chin-Hsiu ;

Tsai, Chang-Youh ;

Chou, Chung-Tei .

CLINICAL RHEUMATOLOGY, 2010, 29 (10) :1155-1161

[10]

Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis [J].

Collin-Osdoby, P ;

Rothe, L ;

Anderson, F ;

Nelson, M ;

Maloney, W ;

Osdoby, P .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (23) :20659-20672

← 1 2 3 4 5 6 →